Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases

References

• Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002;53:849-57
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
   PubMed Web of Science ®Google Scholar
• Barkin RL, Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 2005;12:431-8
   PubMedGoogle Scholar
• Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-9
   PubMed Web of Science ®Google Scholar
• Arnold LM, Meyers AL, Sunderajan P. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 2008;20:187-93
   PubMed Web of Science ®Google Scholar
• Perahia DG, Pritchett YL, Desaiah D, et al. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21:311-17
   PubMed Web of Science ®Google Scholar
• Duloxetine hydrochloride [prescribing information]. Indianapolis, IN: Lilly USA LLC, 2009
   Google Scholar
• Liu X, Ye W, Watson P, et al. Use of benzodiazepines, hypnotics, and anxiolytics in major depressive disorder: association with chronic pain diseases. J Nerv Ment Dis 2010;198:544-50
   PubMed Web of Science ®Google Scholar
• National Committee on Quality Assurance. The state of health care quality. Available from http://www.ncqa.org/Portals/0/Newsroom/SOHC/SOHC_2009.pdf. [Accessed March 24, 2011]
   Google Scholar
• Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-32
   PubMed Web of Science ®Google Scholar
• Sood N, Treglia M, Obenchain RL, et al. Determinants of antidepressant treatment outcome. Am J Manag Care 2000;6:1327-36
   PubMed Web of Science ®Google Scholar
• Katon W, Cantrell CR, Sokol MC, et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 2005;165:2497-503
   PubMed Web of Science ®Google Scholar
• Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:33-41
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010;11:1282-90
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-73
   PubMed Web of Science ®Google Scholar
• Wu E, Greenberg PE, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin 2008;24:2587-95
   PubMed Web of Science ®Google Scholar
• Wu EQ, Greenberg PE, Yang E, et al. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ 2009;12:124-35
   PubMedGoogle Scholar
• Wu E, Greenberg P, Yang E, et al. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin 2008;24:2805-13
   PubMed Web of Science ®Google Scholar
• Red Book. Thomason Reuters. 2011. Available at http://www.redbook.com/redbook/ [Last accessed 24 March 2011]
   Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Barron J, Wahl P, Fisher M, et al. Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. P T 2008;33:532-53
   PubMedGoogle Scholar
• Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006;12:sp11-19
   PubMed Web of Science ®Google Scholar
• Duru OK, Schmittdiel JA, Dyer WT, et al. Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care 2010;16:33-40
   PubMed Web of Science ®Google Scholar
• Piette JD, Heisler M, Ganoczy D, et al. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatr Serv 2007;58:207-12
   PubMed Web of Science ®Google Scholar
• Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther 2009;31:945-61
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Li D, Mao Y, et al. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr 2009;14:326-33
   PubMed Web of Science ®Google Scholar
• Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007;27:481-92
   PubMed Web of Science ®Google Scholar
• Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23:1605-14
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF, Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int Clin Psychopharmacol 2008;23:181-7
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-16
   PubMed Web of Science ®Google Scholar
• Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007;23:1303-18
   PubMed Web of Science ®Google Scholar
• Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008;42:22-34
   PubMed Web of Science ®Google Scholar
• Schueler YB, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2010: published online 10 September 2010, doi: 10.1111/j.1600-0447.2010.01599.x
   Google Scholar
• Mullins CD, Shaya FT, Meng F, et al. Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. Clin Ther 2006;28:297-305
   PubMed Web of Science ®Google Scholar
• Mullins CD, Shaya FT, Meng F, et al. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005;25:660-7
   PubMed Web of Science ®Google Scholar